EyePoint(EYPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EYPT EyePoint

Trading 04-20 09:54:55 EDT

15.11

+0.18

+1.21%

High15.11	Low14.80	Vol57.88K
Open14.85	D1 Closing14.93	Amplitude2.08%
Mkt Cap1.26B	Tradable Cap905.17M	Total Shares83.43M
T/O865.12K	T/O Rate0.10%	Tradable Shares59.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EYPT","market":"US","secType":"STK","nameCN":"EyePoint","latestPrice":15.11,"timestamp":1776693294041,"preClose":14.93,"halted":0,"volume":57876,"delay":0,"changeRate":0.012056262558606813,"floatShares":59905600,"shares":83431950,"eps":-3.17,"marketStatus":"Trading","change":0.18,"latestTime":"04-20 09:54:55 EDT","open":14.85,"high":15.11,"low":14.8,"amount":865121.6508480001,"amplitude":0.020764,"askPrice":15.14,"askSize":103,"bidPrice":15.05,"bidSize":115,"shortable":3,"etf":0,"ttmEps":-3.17,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776715200000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":14.93,"preHourTrading":{"tag":"盘前","latestPrice":14.78,"preClose":14.93,"latestTime":"09:27 EDT","volume":3449,"amount":51014.521145,"timestamp":1776691679308,"change":-0.15,"changeRate":-0.010047,"amplitude":0.134628},"postHourTrading":{"tag":"盘后","latestPrice":14.88159,"preClose":14.93,"latestTime":"18:19 EDT","volume":106257,"amount":1592497.24179,"timestamp":1776464374837,"change":-0.04841,"changeRate":-0.003242,"amplitude":0.007931},"volumeRatio":1.129366,"impliedVol":0.8706,"impliedVolPercentile":0.6853},"requestUrl":"/m/hq/s/EYPT/wiki","defaultTab":"wiki","newsList":[{"id":"2628241872","title":"BRIEF-Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628241872","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628241872?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:44","pubTimestamp":1776372281,"startTime":"0","endTime":"0","summary":"BRIEF-Eyepoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)April 16 (Reuters) - EyePoint Inc EYPT.O:EYEPOINT REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNX8YQB7RFurther company coverage: EYPT.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nTUA4ZSMYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0320765992.SGD","BK4588","EYPT","BK4585","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628464342","title":"EyePoint grants inducement stock options for 362,500 shares to 14 new employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2628464342","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628464342?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:01","pubTimestamp":1776369717,"startTime":"0","endTime":"0","summary":"EyePoint issued inducement stock options covering 362,500 shares to 14 new employees, granted April 15, 2026.Options carry an exercise price of $14.63 per share.Vesting schedule sets 25% to vest on first anniversary of grant date.Remaining options vest in equal monthly installments over next three years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLbbsYPn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4588","SG9999014021.USD","NDAQ","IE00BKPKM429.USD","BK4007","SG9999014039.USD","LU0320765992.SGD","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0889565916.HKD","IE00BN0W2W23.USD","EYPT","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0109394709.USD","SG9999014005.SGD","BK4112","BK4585","SG9999014013.SGD","LU2095319765.USD","LU2210150020.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628287246","title":"EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628287246","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628287246?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:01","pubTimestamp":1776369660,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., April  16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/16/3275791/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQJ","QYLG","QQQ","TQQY","BK4585","GPIQ","BK4007","EYPT","FTEC","QQQM","LU0320765992.SGD",".IXIC","ONEQ","QQQA","SQQQ","QLD","NQmain","BK4588","QDTE","MNQmain","NVIW.SI","IYW","PSQ","QID","NDX","LU0109394709.USD","QQQE","LU0889565916.HKD","QQQY","JEPQ","TQQQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627425864","title":"Assessing EyePoint (EYPT) Valuation After DURAVYU Phase 3 And Manufacturing Expansion Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2627425864","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627425864?lang=en_us&edition=fundamental","pubTime":"2026-04-15 00:08","pubTimestamp":1776182927,"startTime":"0","endTime":"0","summary":"EyePoint (EYPT) is back in focus after an 8-K filing outlined updated investor materials on its lead retinal drug candidate DURAVYU, Phase 3 trial progress, and expanded manufacturing capacity.\nSee our latest analysis for EyePoint.\nEyePoint’s recent 8 K update on DURAVYU appears to have coincided with building momentum, with a 7 day share price return of 10.8% and a 1 year total shareholder return of about 1.5x, even as the year to date share price return remains negative.\nIf you are looking...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/assessing-eyepoint-eypt-valuation-after-duravyu-phase-3-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/assessing-eyepoint-eypt-valuation-after-duravyu-phase-3-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","BK4588","LU0320765992.SGD","LU0109394709.USD","BK4007","EYPT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627446687","title":"EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2627446687","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627446687?lang=en_us&edition=fundamental","pubTime":"2026-04-14 04:42","pubTimestamp":1776112941,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EyePoint Pharmaceuticals ( ($EYPT) ). On April 13, 2026, EyePoint, Inc. posted an updated investor presentation...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eyepoint-highlights-duravyu-phase-3-progress-and-cash-runway?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eyepoint-highlights-duravyu-phase-3-progress-and-cash-runway?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","PRGS","BK4007","BK4588","BK4585","LU2065732104.USD","LU0109394709.USD","EYPT","LU0889565916.HKD","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623439425","title":"U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2623439425","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623439425?lang=en_us&edition=fundamental","pubTime":"2026-03-30 15:35","pubTimestamp":1774856155,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP MorganMarch 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed comp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL4N40I0JN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHB","FBP","COII","BKU","COLB","FDMT","FANG","ICOI","CLMT","CDNL","CCL","COIN","DVN","CEGX","CBSH","DOW","ALMS","CONI","BANC","CHWY","CEG","COIA","DH","FITB","EYPT","AMT","DASX","FIGR","BALY","ASB","APA","FIAT","HIG","CCI","CRC","OZK","EOG","FERG","GM","BSX","CTRA","COYY","DAN","ETR","MMM","DASH","COIW","BOKF","CONL","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621977577","title":"EyePoint Files Complaint Against Ocular Alleging False or Misleading Claims Regarding Duravyu","url":"https://stock-news.laohu8.com/highlight/detail?id=2621977577","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621977577?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:38","pubTimestamp":1774255093,"startTime":"0","endTime":"0","summary":"EyePoint  said Friday it filed a complaint in a Massachusetts court against Ocular Therapeutix , alleging that Ocular made false or misleading claims about the company's lead eye-disease candidate, Duravyu.The company said it is seeking to stop Ocular from making further false statements and to obtain a public retraction, according to a regulatory filing.Ocular didn't immediately respond to MT Newswires' request for comment.EyePoint shares were down 1.1% in premarket activity Monday, while Ocular fell 2.2%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK4007","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","OCUL","EYPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621752671","title":"BRIEF-Eyepoint Files Complaint Against Ocular Therapeutix In Middlesex County Superior Court","url":"https://stock-news.laohu8.com/highlight/detail?id=2621752671","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621752671?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:39","pubTimestamp":1774042778,"startTime":"0","endTime":"0","summary":"BRIEF-Eyepoint Files Complaint Against Ocular Therapeutix In Middlesex County Superior CourtMarch 20  - EyePoint Inc EYPT.O:EYEPOINT INC - FILES COMPLAINT AGAINST OCULAR THERAPEUTIX IN MIDDLESEX COUNTY SUPERIOR COURT FOR  COMMONWEALTH OF MASSACHUSETTS ON MARCH 20, 2026EYEPOINT INC - COMPLAINT ALLEGES OCULAR THERAPEUTIX DISSEMINATED FALSE STATEMENTS ABOUT EYEPOINT AND DURAVYU - SEC FILINGEYEPOINT INC - COMPLAINT ASSERTS DEFAMATION, COMMERCIAL DISPARAGEMENT, AND TORTIOUS INTERFERENCE CLAIMS - SEC FILINGSource text: [ID:n0001193125-26-117745]Further company coverage: EYPT.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0320765992.SGD","BK4585","LU0109394709.USD","BK4588","EYPT","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621175407","title":"EyePoint Sues Ocular Therapeutix Over Alleged Defamation","url":"https://stock-news.laohu8.com/highlight/detail?id=2621175407","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621175407?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:04","pubTimestamp":1774040694,"startTime":"0","endTime":"0","summary":"EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On March 20, 2026, EyePoint, Inc. filed a lawsuit in Middlesex County Superior C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eyepoint-sues-ocular-therapeutix-over-alleged-defamation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eyepoint-sues-ocular-therapeutix-over-alleged-defamation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EYPT","LU0109394709.USD","BK4585","LU0889565916.HKD","OCUL","BK4007","BK4588","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621751717","title":"EyePoint Inc - Files Complaint Against Ocular Therapeutix in Middlesex County Superior Court for  Commonwealth of Massachusetts on March 20, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621751717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621751717?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:35","pubTimestamp":1774038920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EYPT","LU0320765992.SGD","BK4588","LU0889565916.HKD","LU0109394709.USD","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621517487","title":"EyePoint Inc - Complaint Alleges Ocular Therapeutix Disseminated False Statements About EyePoint and Duravyu - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621517487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621517487?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:35","pubTimestamp":1774038920,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU0889565916.HKD","LU0109394709.USD","BK4588","EYPT","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621375103","title":"EyePoint Inc - Complaint Asserts Defamation, Commercial Disparagement, and Tortious Interference Claims - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2621375103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621375103?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:35","pubTimestamp":1774038920,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN4080Y2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0109394709.USD","LU0320765992.SGD","BK4588","BK4007","LU0889565916.HKD","EYPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621751738","title":"EyePoint sues Ocular Therapeutix over alleged false statements about DURAVYU clinical results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621751738","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621751738?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:34","pubTimestamp":1774038851,"startTime":"0","endTime":"0","summary":"EyePoint filed a complaint against Ocular Therapeutix in Middlesex County Superior Court in Massachusetts.The complaint alleges Ocular Therapeutix disseminated false or misleading statements about EyePoint and clinical results for DURAVYU.Additional claims include alleged violations of Massachusetts General Laws Chapter 93A and tortious interference with advantageous business relations.EyePoint is seeking injunctive relief, a public retraction, and monetary damages.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 20, 2026,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDLbgl5XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0320765992.SGD","OCUL","BK4007","BK4588","BK4585","EYPT","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620261652","title":"A Look At EyePoint Pharmaceuticals (EYPT) Valuation Following Recent Mixed Share Price Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2620261652","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620261652?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:06","pubTimestamp":1773860803,"startTime":"0","endTime":"0","summary":"Recent performance snapshot\nEyePoint (EYPT) has drawn attention after mixed recent returns, with the share price up about 7% over the past month but showing a decline over the past 3 months and year to date.\nAt a last close of US$13.90 and a market value of about US$1.12b, investors are weighing this performance against the company’s focus on retinal disease treatments and its developing product pipeline.\nSee our latest analysis for EyePoint.\nThat mix of a 7.42% 30 day share price return...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/a-look-at-eyepoint-pharmaceuticals-eypt-valuation-following","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/a-look-at-eyepoint-pharmaceuticals-eypt-valuation-following","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","BK4588","BK4585","LU0320765992.SGD","LU0109394709.USD","BK4007","EYPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620770574","title":"EyePoint (EYPT) Is Down 14.2% After Weak Q4 Results And DURAVYU Optimism - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2620770574","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620770574?lang=en_us&edition=fundamental","pubTime":"2026-03-18 02:14","pubTimestamp":1773771280,"startTime":"0","endTime":"0","summary":"EyePoint Pharmaceuticals reported fourth-quarter 2025 revenue of US$620,000 versus US$11.59 million a year earlier, with net loss widening to US$67.61 million and basic loss per share from continuing operations rising to US$0.81, while also granting long-term stock options and ending 2025 with cash reportedly sufficient to fund operations into late 2027.\nDespite weaker financial results, investor attention has shifted toward the CEO’s recent purchase of 1,500 shares, analyst optimism linked...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/eyepoint-eypt-is-down-142-after-weak-q4-results-and-duravyu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","BK4007","BK4588","BK4585","LU0109394709.USD","EYPT","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620499416","title":"EyePoint President and CEO Jay S. Duker acquires USD 19,724 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499416","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499416?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:13","pubTimestamp":1773692028,"startTime":"0","endTime":"0","summary":"Jay Duker, President and CEO of EyePoint, acquired 1,500 shares of EyePoint common stock at USD 13.15 per share. The shares were reported as held indirectly, with 100,665 shares beneficially owned following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7bhYXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"EyePoint President and CEO Jay S. Duker acquires USD 19,724 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","BK4588","BK4007","EYPT","LU0320765992.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620460875","title":"EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460875","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460875?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:31","pubTimestamp":1773678689,"startTime":"0","endTime":"0","summary":"Eyepoint Pharma ($EYPT) announced an update on their ongoing clinical study. The COMO phase 3 study from EyePoint Pharmaceuticals, Inc. tests a new...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eyepoints-como-phase-3-trial-puts-long-acting-dme-strategy-in-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eyepoints-como-phase-3-trial-puts-long-acting-dme-strategy-in-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0320765992.SGD","LU0889565916.HKD","BK4007","LU0109394709.USD","BK4585","EYPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619245791","title":"EyePoint reports inducement grants under NASDAQ listing rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2619245791","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619245791?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:16","pubTimestamp":1773659810,"startTime":"0","endTime":"0","summary":"EyePoint (EYPT) granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in ac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQJ","NDX","JEPQ","BK4585","QQQY","QLD","LU0889565916.HKD","NQmain","USJW.SI",".IXIC","TSYW.SI","GPIQ","EYPT","SQQQ","QQQ","QQQM","TQQQ","LU0320765992.SGD","PSQ","LU0109394709.USD","QID","QYLG","USAW.SI","BK4007","QQQE","BK4588","MNQmain","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452157","title":"EyePoint grants 20,000 inducement stock options at USD 13.2 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452157","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452157?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:02","pubTimestamp":1773658929,"startTime":"0","endTime":"0","summary":"EyePoint reported granting non-statutory stock options covering 20,000 shares to six new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The options were granted on March 13, 2026, with an exercise price of USD 13.2 per share. EyePoint said the options have a 10-year term and vest over four years. The awards vest 25% on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following three years.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2ZwWr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","LU2210150020.SGD","LU0109394709.USD","IE00B64PRP62.GBP","BK4112","LU0889565916.HKD","BK4007","LU2210149790.SGD","IE00BN0W2W23.USD","EYPT","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2095319765.USD","SG9999014021.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452694","title":"EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452694","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452694?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA93DWRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU0109394709.USD","BK4588","LU0320765992.SGD","BK4585","EYPT","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eyepointpharma.com","stockEarnings":[{"period":"1week","weight":0.0521},{"period":"1month","weight":0.0946},{"period":"3month","weight":-0.0099},{"period":"6month","weight":0.2837},{"period":"1year","weight":1.6308},{"period":"ytd","weight":-0.1828}],"compareEarnings":[{"period":"1week","weight":0.0452},{"period":"1month","weight":0.0736},{"period":"3month","weight":0.0267},{"period":"6month","weight":0.0689},{"period":"1year","weight":0.349},{"period":"ytd","weight":0.0414}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.047593},{"month":2,"riseRate":0.409091,"avgChangeRate":0.004657},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.012715},{"month":4,"riseRate":0.545455,"avgChangeRate":0.155696},{"month":5,"riseRate":0.380952,"avgChangeRate":0.00075},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.02035},{"month":7,"riseRate":0.619048,"avgChangeRate":0.044584},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024706},{"month":9,"riseRate":0.380952,"avgChangeRate":0.007468},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.047614},{"month":11,"riseRate":0.47619,"avgChangeRate":-0.049639},{"month":12,"riseRate":0.380952,"avgChangeRate":0.116746}],"exchange":"NASDAQ","name":"EyePoint","nameEN":"EyePoint"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"EyePoint(EYPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest EyePoint(EYPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"EyePoint,EYPT,EyePoint股票,EyePoint股票老虎,EyePoint股票老虎国际,EyePoint行情,EyePoint股票行情,EyePoint股价,EyePoint股市,EyePoint股票价格,EyePoint股票交易,EyePoint股票购买,EyePoint股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"EyePoint(EYPT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest EyePoint(EYPT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction